TNFRSF17 and plasma cell myeloma: Since 2015, B-cell maturation antigen (BCMA), a very selective plasma cell (PC) receptor highly expressed in human multiple myeloma (MM) cells, has been the top target antigen for the novel monoclonal antibody (MoAb)- and cell-based immunotherapies [1–6].